long term effects of glp-1 drugs A monthly dose could cut the number shots patients take each year from 52 to 12. Side from the drug — mainly gastrointestinal symptoms — were similar to or Common, uncommon, and rare side

Ultrasound assessments could improve risk stratification for perioperative management

At 12 months, weight loss persisted at around 4%, with variability between agents, most notably liraglutide

A closer look at how GLP-1 medications may impact fertility, PCOS, and reproductive health.

Obesity is the fifth leading risk factor for global deaths with numbers continuing to increase worldwide

Preclinical and initial human studies suggest that glucagon-like peptide-1 receptor agonists may be promising treatments for alcohol use disorder, but existing approved treatments should be used until safety and efficacy is demonstrated in clinical trials.

Glucagon-like peptide1 receptor agonists (GLP-1RAs) have emerged as a transformative class of therapies initially developed for glycemic control in type2 diabetes mellitus